MNTA – Biomaven on SI notes that the heparin-contamination story should, at the very least, win MNTA some brownie points at the FDA for helping the Agency ameliorate the political damage it suffered for not inspecting the supply chain in China.
Further, the FDA presumably had an opportunity to see a practical application of MNTA’s characterization technology. This can’t hurt and might help on the Lovenox ANDA.
Market Data 
Markets 
AI
